Diagnosis of von Willebrand disease (VWD) type 2 usually relies on the discrepancy between the von Willebrand factor (VWF) ristocetin cofactor activity (VWF:RCo) and VWF antigen (VWF:Ag). Type 2B patients can be discriminated from other qualitative VWD variants by using ristocetin-induced platelet agglutination (RIPA) test. The major limitation of RIPA is the requirement of fresh blood sample.
Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination / F. Stufano, L. Baronciani, M.T. Pagliari, F. Franchi, G. Cozzi, I. Garcia Oya, P. Bucciarelli, M. Boscarino, F. Peyvandi. - In: JOURNAL OF THROMBOSIS AND HAEMOSTASIS. - ISSN 1538-7933. - 13:10(2015 Oct), pp. 1806-14-1814. [10.1111/jth.13062]
Evaluation of an heterogeneous group of patients with von Willebrand disease using an assay alternative to ristocetin induced platelet agglutination
F. PeyvandiUltimo
2015
Abstract
Diagnosis of von Willebrand disease (VWD) type 2 usually relies on the discrepancy between the von Willebrand factor (VWF) ristocetin cofactor activity (VWF:RCo) and VWF antigen (VWF:Ag). Type 2B patients can be discriminated from other qualitative VWD variants by using ristocetin-induced platelet agglutination (RIPA) test. The major limitation of RIPA is the requirement of fresh blood sample.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Peyvandi_Stufano_JournalThrombosisHaemostasis_2015.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
184.66 kB
Formato
Adobe PDF
|
184.66 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
